首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1619083

青光眼市场规模、份额、成长分析、按类型、按药物类别、按管理方法、按最终用途、按分布、按地区 - 行业预测，2024-2031 年

Glaucoma Market Size, Share, Growth Analysis, By Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG)), By Drug Class (Beta Blockers, Prostaglandins), By Administration, By End Use, By Distribution, By Region - Industry Forecast 2024-2031

出版日期: 2024年12月18日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球青光眼市场规模估值为81亿美元，从2023年的86.3亿美元成长到2031年的144亿美元，预计在预测期内（2024-2031年）复合年增长率为6.6%。

全球青光眼市场持续成长，主要是由于这种慢性眼科疾病的盛行率不断上升，特别是在高龄化社会和患有慢性眼科疾病的人。微创手术和雷射治疗等诊断和治疗技术的进步进一步支持了市场扩张。然而，一些地区治疗费用上涨和获得医疗服务有限等挑战正在阻碍成长。竞争格局的特点是主要产业参与者的高度活跃，推动了创新景观管理解决方案的持续研究和发展。随着对青光眼的认识、早期检测和治疗方案的改善，全球青光眼市场预计在未来几年将稳定成长，凸显了解决这个严重健康问题的重要性。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东/非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲

竞争资讯

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2023）
主要企业简介
- 公司简介
- 产品系列分析
- 按细分市场分類的份额分析
- 收益与前一年同期比较（2021-2023）

主要企业简介

Aerie Pharmaceuticals（USA）
Akorn, Inc.（USA）
AbbVie Inc.（USA）
Bausch Health Companies Inc.（Canada）
Inotek Pharmaceuticals Corp.（USA）
Merck & Co., Inc.（USA）
Novartis AG（Switzerland）
Pfizer Inc.（USA）
Santen Pharmaceutical Co., Ltd.（Japan）
Glaukos Corporation（USA）
Ocular Therapeutix, Inc.（USA）
Santen Inc.（Japan）
Ono Pharmaceutical Co., Ltd.（Japan）
Nicox SA（France）
Sun Pharmaceutical Industries Ltd.（India）
Visiox Pharma（USA）
TearClear（USA）
MediPrint Ophthalmics（formerly Leo Lens Pharma）（Denmark）
Tarsier Pharma（USA）
Peregrine Ophthalmic（USA）

结论和建议

简介目录

Product Code: SQMIG35A2274

Global Glaucoma Market size was valued at USD 8.1 billion in 2022 and is poised to grow from USD 8.63 billion in 2023 to USD 14.4 billion by 2031, growing at a CAGR of 6.6% during the forecast period (2024-2031).

The global glaucoma market is experiencing consistent growth, primarily fueled by the rising prevalence of this chronic eye condition, particularly among the aging population and those with chronic eye diseases. Advancements in diagnostic and treatment technologies, including minimally invasive surgeries and laser therapies, further bolster market expansion. However, challenges such as high treatment costs and limited healthcare access in certain areas pose obstacles to growth. The competitive landscape is marked by significant activity among key industry players, driving continuous research and development for innovative glaucoma management solutions. As awareness, early detection, and improved treatment options progress, the global glaucoma market is anticipated to grow steadily in the coming years, underscoring the importance of addressing this critical health issue.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glaucoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glaucoma Market Segmental Analysis

Global Glaucoma Market is segmented by type, drug class, administration, end use, distribution and region. Based on type, the market is segmented into closed angle glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and others. Based on drug class, the market is segmented into beta blockers, prostaglandins, alpha adrenergic agonist, carbonic anhydrase inhibitors, combination drugs and others. Based on administration, the market is segmented into oral, injections, intravitreal and other. Based on end use, the market is segmented into hospitals, specialty centers and others. Based on distribution, the market is segmented into hospital, online and retail. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glaucoma Market

A significant impetus for the global glaucoma market stems from the escalating prevalence of the condition across the globe. This surge is primarily driven by an aging population and a rise in chronic illnesses, including diabetes and hypertension, which heighten the likelihood of glaucoma development. Given that glaucoma is a major contributor to irreversible blindness, there is an urgent requirement for early detection, diagnosis, and treatment options. Consequently, this situation stimulates demand for cutting-edge glaucoma management solutions, encompassing advanced diagnostic equipment, effective medications, and surgical treatments, all aimed at improving patient outcomes and reducing the risk of vision loss.

Restraints in the Global Glaucoma Market

The global glaucoma market faces significant restraints primarily due to limited awareness and inadequate routine screening practices for this condition in various regions. As glaucoma often presents asymptomatically in its early stages, the absence of regular eye exams complicates timely diagnosis. This lack of awareness among both the general public and healthcare providers can result in late-stage diagnosis and subsequent irreversible vision loss. Additionally, the high costs associated with managing glaucoma-encompassing medications, surgical interventions, and long-term care-pose substantial barriers to access, particularly for patients in low- and middle-income countries, further exacerbating the challenges in glaucoma management and treatment.

Market Trends of the Global Glaucoma Market

The global glaucoma market is witnessing a significant trend towards the adoption of advanced diagnostic technologies and innovative treatment modalities, driven by the urgent need for early detection and management of this potentially debilitating eye disease. As awareness increases regarding the irreversible vision loss associated with glaucoma, healthcare providers are prioritizing regular screenings and advanced imaging techniques for timely diagnosis. Technologies like optical coherence tomography (OCT), visual field testing, and advanced tonometry are increasingly utilized to enhance diagnostic accuracy and patient monitoring. This trend is fostering a robust market environment, as both established and emerging players invest in cutting-edge solutions to better address patient needs and optimize treatment outcomes.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Glaucoma Market Size by Type & CAGR (2024-2031)

Market Overview
Closed Angle Glaucoma (CAG)
Open Angle Glaucoma (OAG)
Secondary Glaucoma
Congenital Glaucoma
Others

Global Glaucoma Market Size by Drug Class & CAGR (2024-2031)

Market Overview
Beta Blockers
Prostaglandins
Alpha Adrenergic Agonist
Carbonic Anhydrase Inhibitors
Combination Drugs
Others

Global Glaucoma Market Size by Administration & CAGR (2024-2031)

Market Overview
Oral
Injections
Intravitreal
Other

Global Glaucoma Market Size by End Use & CAGR (2024-2031)

Market Overview
Hospitals
Specialty Centers
Others

Global Glaucoma Market Size by Distribution & CAGR (2024-2031)

Market Overview
Hospital
Online
Retail

Global Glaucoma Market Size & CAGR (2024-2031)

North America (Type, Drug Class, Administration, End Use, Distribution)
- US
- Canada
Europe (Type, Drug Class, Administration, End Use, Distribution)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug Class, Administration, End Use, Distribution)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug Class, Administration, End Use, Distribution)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug Class, Administration, End Use, Distribution)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Aerie Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akorn, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inotek Pharmaceuticals Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glaukos Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocular Therapeutix, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ono Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nicox S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Visiox Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TearClear (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediPrint Ophthalmics (formerly Leo Lens Pharma) (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tarsier Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Peregrine Ophthalmic (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments